Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LFST
LFST logo

LFST Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
6.400
Open
6.300
VWAP
6.33
Vol
1.89M
Mkt Cap
2.44B
Low
6.225
Amount
11.99M
EV/EBITDA(TTM)
30.25
Total Shares
382.78M
EV
2.46B
EV/OCF(TTM)
16.86
P/S(TTM)
1.72
LifeStance Health Group, Inc. is a reimagining mental health company. The Company is focused on providing virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Its patient-focused platform combines differentiated clinical capabilities with a personalized, digitally powered patient experience designed to transform patient access and treatment. Its clinicians offer patients a comprehensive, multidisciplinary suite of mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders and post-traumatic stress disorder. It employs approximately 7,400 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.
Show More

Events Timeline

(ET)
2026-02-26
08:30:00
JPMorgan Acts as Sole Bookrunner for Deal Range $7.04-$7.41
select
2026-02-25 (ET)
2026-02-25
17:50:00
J.P. Morgan Acts as Underwriter for Offering
select
2026-02-25
17:00:00
LifeStance Health Plans to Offer 25M Shares
select
2026-02-25
06:20:00
LifeStance Q4 Revenue $382.2M Exceeds Expectations
select
2026-02-25
06:20:00
Sees Q1 Center Margin of $118M to $132M
select

News

moomoo
6.0
02-26moomoo
LIFESTANCE HEALTH GROUP INC: UBS Increases Target Price from $10 to $12
  • Price Increase Announcement: LifeStance Health Group Inc. has raised its target price from $10 to $12.
  • Market Impact: This adjustment reflects the company's growth and performance expectations in the healthcare sector.
seekingalpha
9.5
02-26seekingalpha
LifeStance Health Group Reports Record Q4 2025 Earnings and Strategic Outlook
  • Record Performance: LifeStance achieved a record fourth-quarter revenue of $382 million in 2025, representing a 17% year-over-year increase, primarily driven by an 18% rise in visit volumes to 2.4 million, highlighting the company's strong growth potential in the mental health sector.
  • Profitability Improvement: The company achieved double-digit adjusted EBITDA margins for the first time, reaching 12.8%, with a full-year adjusted EBITDA of $158 million, reflecting significant operational efficiency improvements and enhanced financial discipline.
  • Positive Outlook: LifeStance projects 2026 revenue between $1.615 billion and $1.655 billion, with center margins of $526 million to $550 million, and plans to invest $20 million to $30 million in EHR implementation over the next two years, further driving business growth.
  • Shareholder Return Plan: The company announced a $100 million share repurchase program, demonstrating confidence in future cash flows while continuing to explore M&A opportunities to enhance market competitiveness and expand service capabilities.
seekingalpha
8.5
02-25seekingalpha
LifeStance Health to Offer 25 Million Shares
  • Stock Offering Announcement: LifeStance Health Group disclosed that certain stockholders intend to offer 25 million shares of common stock, with a par value of $0.01 per share, indicating that the proceeds will solely benefit the selling stockholders and not the company itself.
  • No Revenue Impact: The company will not sell any shares in this offering, thus it will not receive any proceeds, a strategy that may aim to optimize shareholder structure rather than raise direct capital.
  • Repurchase Authorization: Additionally, the company has authorized the concurrent repurchase of 7 million shares from the underwriter upon completion of the offering, with the repurchase price matching that paid by the underwriter to the selling stockholders, reflecting confidence in its stock value.
  • Market Reaction Expectations: This stock offering and repurchase plan may lead to short-term volatility in LifeStance Health's stock price; however, given the company's lack of direct involvement in the proceeds, the overall impact may remain neutral.
moomoo
7.0
02-25moomoo
Lifestance Health Stock Rises 7.8% Following Company’s FY26 Revenue Forecast Exceeding Expectations
  • Lifescience Health Shares: Lifescience Health shares have increased by 7.8% following a positive forecast.

  • FY26 Revenue Performance: The company's revenue for FY26 is projected to exceed estimates, indicating strong financial performance.

seekingalpha
9.5
02-25seekingalpha
LifeStance Health Group Q4 Revenue Exceeds Expectations
  • Significant Revenue Growth: LifeStance Health Group reported Q4 revenue of $382.2 million, reflecting a 17.4% year-over-year increase, surpassing market expectations by $3.69 million, indicating strong demand and competitive positioning in the mental health services sector.
  • Clinical Team Expansion: The clinician base grew by 9% to 8,040, with a net increase of 44 in Q4 and 657 for the full year, demonstrating the company's success in attracting and retaining professional talent, which enhances service capacity.
  • Increased Visit Volumes: Q4 visit volumes rose by 18% to 2.4 million, while full-year volumes increased by 14% to 9.0 million, reflecting ongoing improvements in customer demand and market penetration, driving overall business growth.
  • Optimistic Future Outlook: For 2026, the company expects revenue between $1.615 billion and $1.655 billion, with center margins projected at $526 million to $550 million and adjusted EBITDA between $185 million and $205 million, showcasing confidence in future growth and clear strategic planning.
Benzinga
9.0
2025-12-26Benzinga
Biohaven Ltd's Depression Drug Trial Fails to Meet Primary Endpoint, Shares Plunge 14.3%
  • Drug Trial Failure: Biohaven Ltd announced that its depression drug BHV-7000 failed to significantly reduce depressive symptoms in a six-week clinical trial, causing shares to plummet 14.3% to $9.27 in pre-market trading, reflecting a substantial decline in market confidence regarding its R&D capabilities.
  • Severe Market Reaction: The news of the trial's failure triggered panic among investors, leading to a rapid decline in Biohaven's stock price during pre-market trading, indicating the high sensitivity of the biopharmaceutical sector to clinical outcomes, which may impact the company's future financing and R&D plans.
  • Increased Competitive Pressure: With Biohaven's drug trial failure, market attention shifts to other competitors, particularly in the depression treatment space, potentially leading investors to reassess the market outlook and investment value of related companies.
  • Wider Industry Implications: Biohaven's failure could have a ripple effect across the biopharmaceutical industry, particularly in terms of R&D investments and clinical trial designs, prompting other companies to more cautiously evaluate their drug development strategies.
Wall Street analysts forecast LFST stock price to rise
8 Analyst Rating
Wall Street analysts forecast LFST stock price to rise
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
8.00
Averages
9.07
High
10.00
Current: 0.000
sliders
Low
8.00
Averages
9.07
High
10.00
Barclays
Overweight
maintain
$8 -> $9
AI Analysis
2026-03-06
Reason
Barclays
Price Target
$8 -> $9
AI Analysis
2026-03-06
maintain
Overweight
Reason
Barclays raised the firm's price target on LifeStance to $9 from $8 and keeps an Overweight rating on the shares. The firm remains "optimistic" that the company's recent investments will continue to drive productivity and growth over the next few years. It sees a buying opportunity following the recent share pullback.
UBS
Buy
maintain
$10 -> $12
2026-02-26
Reason
UBS
Price Target
$10 -> $12
2026-02-26
maintain
Buy
Reason
UBS raised the firm's price target on LifeStance to $12 from $10 and keeps a Buy rating on the shares. LifeStance posted another solid quarter, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LFST
Unlock Now

Valuation Metrics

The current forward P/E ratio for LifeStance Health Group Inc (LFST.O) is 239.18, compared to its 5-year average forward P/E of -2.90. For a more detailed relative valuation and DCF analysis to assess LifeStance Health Group Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.90
Current PE
239.18
Overvalued PE
95.08
Undervalued PE
-100.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
44.61
Current EV/EBITDA
17.29
Overvalued EV/EBITDA
77.96
Undervalued EV/EBITDA
11.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.93
Current PS
1.72
Overvalued PS
5.17
Undervalued PS
0.70

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what stocks will gain the most today
Intellectia · 38 candidates
Market Cap: >= 500.00MRegion: USPrice Change Pct: >= $0.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEOne Day Rise Prob: >= 70One Day Predict Return: >= 3.0%
Ticker
Name
Market Cap$
top bottom
CAC logo
CAC
Camden National Corp
839.62M
BAK logo
BAK
Braskem SA
1.49B
OUT logo
OUT
OUTFRONT Media Inc
4.20B
FBP logo
FBP
First BanCorp
3.51B
HLLY logo
HLLY
Holley Inc
503.73M
CFG logo
CFG
Citizens Financial Group Inc
27.81B
What stock to buy under 10
Intellectia · 54 candidates
Price: <= $10.00Beta: ModerateRiskRevenue 5yr Cagr: >= 5Weekly Average Turnover: >= 1,000,000Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
MFG logo
MFG
Mizuho Financial Group Inc
104.37B
LYG logo
LYG
Lloyds Banking Group PLC
81.38B
STLA logo
STLA
Stellantis NV
37.25B
NMR logo
NMR
Nomura Holdings Inc
26.35B
CSAN logo
CSAN
Cosan SA
4.02B
INTR logo
INTR
Inter & Co Inc
3.88B
energy ai and banking healthcare
Intellectia · 59 candidates
Market Cap: 300.00M - 10.00BPrice: <= $10.00Weekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 10.0%
Ticker
Name
Market Cap$
top bottom
UWMC logo
UWMC
UWM Holdings Corp
9.26B
IBRX logo
IBRX
Immunitybio Inc
6.82B
RIG logo
RIG
Transocean Ltd
5.10B
BGC logo
BGC
Bgc Group Inc
4.27B
INTR logo
INTR
Inter & Co Inc
3.88B
DNN logo
DNN
Denison Mines Corp
3.36B

Whales Holding LFST

I
Integral Health Asset Management, LLC
Holding
LFST
-2.33%
3M Return
T
TPG Capital, L.P.
Holding
LFST
-10.15%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is LifeStance Health Group Inc (LFST) stock price today?

The current price of LFST is 6.37 USD — it has increased 2.08

What is LifeStance Health Group Inc (LFST)'s business?

LifeStance Health Group, Inc. is a reimagining mental health company. The Company is focused on providing virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Its patient-focused platform combines differentiated clinical capabilities with a personalized, digitally powered patient experience designed to transform patient access and treatment. Its clinicians offer patients a comprehensive, multidisciplinary suite of mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders and post-traumatic stress disorder. It employs approximately 7,400 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.

What is the price predicton of LFST Stock?

Wall Street analysts forecast LFST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFST is9.07 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is LifeStance Health Group Inc (LFST)'s revenue for the last quarter?

LifeStance Health Group Inc revenue for the last quarter amounts to 382.19M USD, increased 17.43

What is LifeStance Health Group Inc (LFST)'s earnings per share (EPS) for the last quarter?

LifeStance Health Group Inc. EPS for the last quarter amounts to 0.03 USD, decreased -250.00

How many employees does LifeStance Health Group Inc (LFST). have?

LifeStance Health Group Inc (LFST) has 10961 emplpoyees as of April 01 2026.

What is LifeStance Health Group Inc (LFST) market cap?

Today LFST has the market capitalization of 2.44B USD.